Intracranial hemangioma

Summary

Intracranial hemangioma (MONDO:0002328) is a disease. A subtype of central nervous system hemangioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intracranial hemangioma
Mondo ID	MONDO:0002328
DOID	DOID:2517
ICD-10-CM	D18.02
NCIT	C3633
SNOMED CT	93468003
UMLS	C0154050
MedGen	57582
Anatomy (UBERON)	UBERON:0000955
Is cancer (heuristic)	no

Also known as: angioma of intracranial structure · angioma of the intracranial structure · brain hemangioma · hemangioma of brain · hemangioma of intracranial structure · hemangioma of intracranial structures · hemangioma of the intracranial structure · intracranial angioma · intracranial hemangioma

Disease family

This is a subtype of central nervous system hemangioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › nervous system benign neoplasm › central nervous system organ benign neoplasm › central nervous system hemangioma › intracranial hemangioma

Related subtypes (1): hemangioma of peripheral nerve

Subtypes (4): intracranial cavernous angioma, brain hemangioma, cerebellar hemangioblastoma, brain stem hemangioblastoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.